NEW YORK – Ideaya Biosciences on Wednesday said the first patient with a homologous recombination repair deficient (HRD) cancer has received its selective PARG inhibitor IDE161 in a Phase I trial.
PARG is a mechanistically differentiated target in the same DNA damage repair pathway as PARP. Ideaya believes IDE161 could be a first-in-class synthetically lethal treatment for cancer patients with HRD, particularly patients with estrogen receptor-positive HER2-negative breast cancer, ovarian cancer, and other solid tumors who lack treatment options.
The first patient in the recently launched Phase I trial received IDE161 at MD Anderson Cancer Center. In this trial, researchers led by principal investigator Timothy Yap, associate professor of investigational cancer therapeutics at MD Anderson, will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of IDE161 at different doses in cancer patients with HRD.
At the American Association for Cancer Research's annual meeting this week, Ideaya presented preclinical data on IDE161. "Based on its preclinical tolerability profile, IDE161 may also be suitable for evaluation with several distinct classes of combination agents, providing multiple paths to demonstrate patient benefit in these populations," Ideaya Chief Medical Officer Darrin Beaupre said in a statement.